Association of TGF-β1 with cystatin-C in patients with diabetic nephropathy

被引:0
|
作者
Jasem, Ali Hassan [1 ]
Haddad, Nazar S. [2 ]
Yaseen, Nassar Taha [3 ]
Alrufaie, Mohauman Mohammed [4 ]
机构
[1] Al Faihaa Teaching Hosp, Basrah, Iraq
[2] Univ Basrah, Coll Med, Iraqi Board Med Specializat Clin Chem FIBMS Chem, Amer Assoc Clin Chem FAACC, Basrah, Iraq
[3] Faiha Specialized Diabet Endocrine & Metab Ctr FD, Basrah, Iraq
[4] Univ Kufa, Fac Sci, Dept Chem, Najaf, Iraq
关键词
Type-2 Diabetes Mellitus; TGF-beta; 1; Cystatin-C; BETA;
D O I
10.35975/apic.v28i1.2399
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background & Objective: Diabetes is considered a condition that is characterized by an increase in oxidative stress and inflammation. Transforming growth factor-beta (TGF-beta) belongs to the TGF-beta subfamily of the TGF-beta superfamily. Numerous biological processes, such as cell growth, differentiation, adhesion, proliferation, tissue repair, morphogenesis, and apoptosis, are regulated by the TGF-beta subfamily. Five TGF-beta isoforms in this subfamily have been found in vertebrates; however, only TGF-beta 1-3 has been demonstrated to be expressed in mammals. Methodology: The current research comprised of a total of 130 individuals, all of whom were placed into one of three primary groups ; 50 (25 males and 25 females) diabetic patients without nephropathy; 50 (25 males and 25 females) diabetic patients with nephropathy as cases, and 30 (15 males and 15 females) persons in good health, who were of the same age as the patients being studied. In order to measure the concentrations of the parameters, the standard procedures and techniques were used. Results: The mean value of serum TGF-beta 1was significantly higher in diabetic patients without nephropathy and diabetic patients with nephropathy (40.19 +/- 3.56 ng/ml),(51.21 +/- 5.20 ng/ml) respectively as compared to controls (24.80 +/- 3.51 ng/ml) with a high significant difference (P < 0.01). The level of TGF beta 1 showed a positive correlation in the study population with fasting blood sugar (r = 0.273, P = 0.006), creatinine (r = 0.546, P = 0.004), and cystatin C (r = 0.597, P = 0.005). The main finding of the present study was that the mean value of serum TGF-beta 1 in diabetic patients without nephropathy was 40.19 +/- 3.56, and for diabetic patients with nephropathy 51.21 +/- 5.20, while for controls was 24.80 +/- 3.51, a significant difference (P < 0.05). In addition, there was a statistically significant and positive link between the blood TGF 1 levels and the serum creatinine levels of the individuals who participated in the study (r = 0.611, P = 0.003). In addition, patients who had diabetes for a longer period of time (more than five years) had higher levels of TGF beta 1 than those who had just been diagnosed with the condition. This difference, however, was not statistically significant (P > 0.05), which may be due to the fact that the level of TGF 1 rises with increasing duration of the participant's cases. Conclusion: There is no significant correlation between cystatin-C with fasting blood sugar. There was a statistically significant and positive link between the blood TGF-beta 1 levels and the serum creatinine and cystatin-C levels.
引用
收藏
页码:151 / 154
页数:4
相关论文
共 50 条
  • [21] Tetrahydroxystilbene glucoside ameliorates diabetic nephropathy in rats Involvement of SIRT1 and TGF-β1 pathway
    Li, Cairong
    Cai, Fei
    Yang, Yinqiao
    Zhao, Xinyuan
    Wang, Chun
    Li, Juan
    Jia, Yanlong
    Tang, Jing
    Liu, Qing
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2010, 649 (1-3) : 382 - 389
  • [22] MicroRNA-27a adjusts diabetic nephropathy patients and inhibits TGF-β/Smad signaling pathway
    Zou, Xueqin
    Jiang, Min
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 10 (10): : 14266 - 14274
  • [23] Mendelian randomization study supports the causal association between serum cystatin C and risk of diabetic nephropathy
    Feng, Baiyu
    Lu, Yu
    Ye, Lin
    Yin, Lijun
    Zhou, Yingjun
    Chen, Anqun
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [24] Protective role of low-dose TGF-β1 in early diabetic nephropathy induced by streptozotocin
    Ma, Xiaodong
    Ding, Jingjing
    Min, Haiyan
    Wen, Yanting
    Gao, Qian
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2013, 17 (03) : 752 - 758
  • [25] Genome-wide association analysis of cystatin-C kidney function in continental Africa
    Mayanja, Richard
    Machipisa, Tafadzwa
    Soremeku, Opeyemi
    Kamiza, Abram B.
    Kintu, Christopher
    Kalungi, Allan
    Kalyesubula, Robert
    Sande, Obondo J.
    Jjingo, Daudi
    Fabian, June
    Robinson-Cohen, Cassianne
    Franceschini, Nora
    Nitsch, Dorothea
    Nyirenda, Moffat
    Zeggini, Eleftheria
    Morris, Andrew P.
    Chikowore, Tinashe
    Fatumo, Segun
    EBIOMEDICINE, 2023, 95
  • [26] TGF-β1-Induced Epithelial-to-Mesenchymal Transition and Therapeutic Intervention in Diabetic Nephropathy
    Hills, Claire E.
    Squires, Paul E.
    AMERICAN JOURNAL OF NEPHROLOGY, 2010, 31 (01) : 68 - 74
  • [27] Chrysophanol Inhibits the Progression of Diabetic Nephropathy via Inactivation of TGF-β Pathway
    Guo, Chuan
    Wang, Yarong
    Piao, Yuanlin
    Rao, Xiangrong
    Yin, Dehai
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2020, 14 : 4951 - 4962
  • [28] β2-microglobulin and cystatin C in type 2 diabetes:: Assessment of diabetic nephropathy
    Aksun, SA
    Özmen, D
    Özmen, B
    Parildar, Z
    Mutaf, I
    Turgan, N
    Habif, S
    Kumanliogluc, K
    Bayindir, O
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2004, 112 (04) : 195 - 200
  • [29] Primary IgA nephropathy is more severe in TGF-β1 high secretor patients
    Brezzi, Brigida
    Del Prete, Dorella
    Lupo, Antonio
    Magistroni, Riccardo
    Gomez-Lira, Macarena
    Bernich, Patrizia
    Anglani, Franca
    Mezzabotta, Federica
    Turco, Alberto
    Furci, Luciana
    Ceol, Monica
    Antonucci, Francesco
    Abaterusso, Cataldo
    Bonfante, Luciana
    D'Angelo, Angela
    Albertazzi, Alberto
    Gambaro, Giovanni
    JOURNAL OF NEPHROLOGY, 2009, 22 (06) : 747 - 759
  • [30] Urinary TGF-β1 reduction related to a decrease of systolic blood pressure in patients with type 2 diabetes and clinical diabetic nephropathy
    Bertoluci, Marcello Casaccia
    Uebel, Deise
    Schmidt, Alexandre
    Clemo, Fulvio
    Thomazelli, Santos
    Oliveira, Fabio Ramos
    Schmid, Helena
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2006, 72 (03) : 258 - 264